Added to YB: 2025-09-25
Pitch date: 2025-09-23
GNFT [neutral]
Genfit S.A.
+161.57%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
Genfit S.A., together with its subsidiaries, engages in the research and development of medicines and diagnostic solutions in France and internationally.
Market Cap
EUR 651.3M
Pitch Price
EUR 3.11
Price Target
N/A
Dividend
N/A
EV/EBITDA
-13.55
P/E
-7.55
EV/Sales
9.89
Sector
Biotechnology
Category
growth
Genfit (GNFT France): pipeline reshaped as visibility extends into the next decade
GNFT (quick overview): Discontinued VS-01 program but extends cash runway beyond 2028 via Ipsen milestones/royalty financing. Lead asset G1090N safety/efficacy data by year-end, proof-of-concept 2026. GNS561 cholangiocarcinoma readouts coming soon. Focused oncology/liver pipeline with financial flexibility.
Read full article (2 min)